• United Therapeutics Corporation has already reported first-quarter 2026 results, with sales of US$781.5 million and net income of US$274.9 million, both lower than the same period last year and below analyst expectations.
• The earnings shortfall contrasts with earlier optimism driven by positive ralinepag Phase 3 data and pipeline milestones in pulmonary disease and organ technologies, sharpening investor focus on how reliably current products can fund future innovation.
• Against this backdrop of softer quarterly earnings, we'll examine how weaker year-on-year revenue and profit trends may reshape United Therapeutics' investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

United Therapeutics Investment Narrative Recap

To be comfortable owning United Therapeutics today, you need to believe its pulmonary and organ-technology pipeline can offset pressure on its established PAH drugs. The softer Q1 2026 results, with revenue and earnings slipping year on year and missing expectations, refocus attention on whether current cash flows can consistently support that innovation. For now, the most immediate catalyst remains regulatory progress for Tyvaso in idiopathic pulmonary fibrosis, while a key risk is intensifying competition for treprostinil-based therapies.

Against this earnings backdrop, the recent publication and success of the TETON IPF studies for Tyvaso stand out. Those data underpin one of United Therapeutics’ most important potential growth drivers, even as quarterly numbers remind investors that execution in the existing PAH and pulmonary franchise matters for funding that opportunity. How regulators respond to the planned filings for an IPF label will likely influence how investors weigh short term earnings softness against longer term pipeline potential.

Yet investors should also weigh how growing competition for Tyvaso and Remodulin could pressure pricing and volumes over time...

United Therapeutics’ narrative projects $4.4 billion revenue and $1.8 billion earnings by 2029.

Uncover how United Therapeutics' forecasts yield a $644.08 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Before this weaker quarter, the most optimistic analysts were banking on revenue hitting about US$4.6 billion and earnings near US$2.1 billion by 2028, which assumes the IPF and PAH programs deliver far more upside than the baseline view. Compared with consensus, that is a meaningfully more optimistic narrative, and this earnings miss raises fair questions about whether such aggressive assumptions on future growth and margin resilience still hold.

Explore 5 other fair value estimates on United Therapeutics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your United Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.